Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 13:58 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in...
October 03, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October...
September 19, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the...
September 05, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on...
August 26, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Participation in September Investor Conferences

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....
August 06, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August...
August 04, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of...
July 28, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will...
July 02, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1,...
June 24, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R...